EICHORCondition: Moderate to Severe Atopic Dermatitis · Sponsor: Nektar Therapeutics
This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with moderate to severe atopic dermatitis. The estimated duration is 15-35 days for screening, an Induction Period of 16 weeks, a Maintenance Period from Week 16-Week 52, and a Posttreatment Follow-Up Period for an additional year up to approximately Week 104 for all patients. Patients with a response at Week 16 (end of induction therapy) will be re-randomized for the maintenance therapy period.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Nektar Investigative Site | Bryant, Arkansas, United States | — |
| Nektar Investigative Site | Fountain Valley, California, United States | — |
| Nektar Investigative Site | Los Angeles, California, United States | — |
| Nektar Investigative Site | Los Angeles, California, United States | — |
| Nektar Investigative Site | Los Angeles, California, United States | — |
| Nektar Investigative Site | Santa Monica, California, United States | — |
| Nektar Investigative Site | Hialeah, Florida, United States | — |
| Nektar Investigative Site | Hollywood, Florida, United States | — |
| Nektar Investigative Site | Miami, Florida, United States | — |
| Nektar Investigative Site | Miami Lakes, Florida, United States | — |
| Nektar Investigative Site | St. Petersburg, Florida, United States | — |
| Nektar Investigative Site | Tampa, Florida, United States | — |
+ 95 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06136741